Mirati Therapeutics Inc (MRTX) WACC Analysis

As of May 25, 2025, Mirati Therapeutics Inc (MRTX) carries a Weighted Average Cost of Capital (WACC) of 6.4%. WACC reflects the blended rate Mirati Therapeutics Inc must pay to both equity and debt holders.

Within that, the cost of equity is 7.1%, the cost of debt is 5.0%, and the effective tax rate is 26.2%.

Breakdown of WACC Components

• Long-term bond rate: 3.9% – 4.4%
• Equity market risk premium: 4.6% – 5.6%
• Adjusted beta: 0.71 – 1.13
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 1

What It Means for Investors

With a selected WACC of 6.4%, Mirati Therapeutics Inc must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.